CODX Co Diagnostics Inc

New York City, New York – MedTech Outlook’s 2019 Top 10 In-Vitro Diagnostics providers have been announced, including Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests and client of BDA International. The publication contains a discussion with Co-Diagnostics CEO Dwight Egan on a variety of subjects, including the company’s history, the applications of their technology, and how they expect to make their mark on the growing diagnostics (and particularly the polymerase chain reaction, or PCR) sector. 

Mr. Egan also describes how their proprietary CoPrimer™ platform reduces errors and improves efficiency of PCR reactions:

 “CoPrimers are the ultimate product for flexibility in multiplex PCR for delivering great reductions in costs and turnaround times in the lab and driving laboratory efficiencies. The fact that we’ve eliminated [primer dimers] now enables us to test a lot of different targets concurrently in the same reaction. It also enables us to have the flexibility for assay interchangeability.”

Release of the interview follows recent news by Co-Diagnostics that their highly specific multiplex test for Zika, dengue, and chikungunya was enthusiastically received at CARPHA 2019, and that domestic sales of their mosquito vector control products have commenced. Analysts from H.C. Wainwright and Maxim Group recently set a price target of $2.00 for CODX.

MedTech Outlook magazine monitors and informs about MedTech trends, challenges, and solutions worldwide to assist purchasers/procurers, decision maters, and heads of operations/healthcare managers with peer-vetted, authoritative contributions. The interview in full can be found here: https://bit.ly/2Y8quT0

About BDA International, Inc.:

BDA International is an independent global Investor Relations firm offering a wide range of IR-related analysis, research and advisory services. In particular, we provide and are compensated for service packages that include strategic action plans and investor/market perception studies to help entities improve communication with customers and investors, and to increase their visibility. BDA International has received no direct compensation related to this release but its principles may also in some circumstances hold some of shares of client companies in our personal portfolios, including CODX. BDA International accepts sole responsibility for the content and distribution of the foregoing release, which does not contain any previously unpublished or non-public information. Parties interested in learning more about the relationship between BDA and CODX may do so via the contact information at the bottom of this release.

Disclaimer

Co-Diagnostics is a client of BDA International. The information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained in this analysis reflect our current judgment and are subject to change without notice. We do not accept any responsibility or liability for any losses, damages or costs arising from an investor’s or other person’s reliance on or use of this analysis. This analysis is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities, nor a recommendation of any security, although members of the BDA may at times hold a position in the company covered within the article. Past gains are not a representative of future gains. The opinions herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. When used herein, the words “anticipate,” “intend,” “estimate,” “believe,” “expect,” “plans,” “should,” “potential,” “forecast,” and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A company’s actual results could differ materially from those described in any forward-looking statements contained herein. BDA is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. We recommend that you use the information found herein as an initial starting point for conducting your own research in order to determine your own personal opinion of the companies discussed herein before deciding whether or not to invest. You should seek such investment, tax, financial, accounting or legal advice appropriate for your particular circumstances. Information about many publicly traded companies and other investor resources can be found at www.sec.gov. Investing in securities is speculative and carries risk.

Investor Relations Contact:                                                                                BDA International   www.bda-ir.com

dost@bda-ir.com

Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Mar 2024 to Apr 2024

Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Apr 2023 to Apr 2024